XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial BERKELEY, Calif., Nov. 20, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA ...

A stepped regimen of amlodipine 5-10 mg/day with addition of perindopril 4 or 8 mg/day as required ('modern' regimen) was compared with a 'traditional' regimen of atenolol 50-100 mg/day with ...

Perindopril and amlodipine are individually approved for the treatment of hypertension and coronary artery disease. RELATED: NDA Accepted for Review for Fixed-Dose Combo Hypertension Drug ...

With amlodipine overall, 3.9% of patients developed pedal edema, with no differences seen between the amlodipine/perindopril and amlodipine/HCTZ groups. “Pending trial evidence comparing the effects ...

Emerson and Dr. Feldstein oversaw the 837-patient Phase III Perindopril Amlodipine for the Treatment of Hypertension (PATH) trial, which demonstrated that the FDC of perindopril arginine combined ...

The blood pressure-lowering arm of ASCOT (ASCOT-BPLA) randomized 19,342 such hypertensive patients, aged 40 to 79 years, to either amlodipine, adding perindopril as required, or to atenolol ...

Research Highlights: A study of three pills that combined two types of blood-pressure-lowering medications into one pill found that all combinations worked equally well among adults in India.

Momentum Money Heroes Picture This: Huawei Photo Competition - Enter and win! Prevent & Protect with Sanofi Sustainable Impact with Standard Bank RU120 - Rhodes celebrates 120 years Government ...

XOMA Corporation ( XOMA) recently announced encouraging data from a phase III study PATH (Perindopril Amlodipine for the Treatment of Hypertension: n=837), which evaluated the fixed-dose ...

XOMA Corporation announced encouraging data from a phase III study PATH ...